Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.28 (
chloramphenicol acetyltransferase
)
5,100
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To study the molecular basis of tissue-specific expression of the
GLUT4
/muscle-fat facilitative glucose transporter gene, we generated lines of transgenic mice carrying 2.4 kilobases of the 5'-flanking region of the human
GLUT4
gene fused to a
chloramphenicol acetyltransferase
(
CAT
) reporter gene (hGLUT4[2.4]-
CAT
). This reporter gene construct was specifically expressed in tissues that normally express
GLUT4
mRNA, which include both brown and white adipose tissues as well as cardiac, skeletal, and smooth muscle. In contrast,
CAT
reporter activity was not detected in brain or liver, two tissues that do not express the
GLUT4
gene. In addition, the relative levels of
CAT
mRNA driven by the human
GLUT4
promoter in various tissues of these transgenic animals mirrored those of the endogenous mouse
GLUT4
mRNA. Since previous studies have observed alterations in
GLUT4
mRNA levels induced by fasting and refeeding (Sivitz, W. I., DeSautel, S. L., Kayano, T., Bell, G. I., and Pessin, J. E. (1989) Nature 340, 72-74), the regulated expression the hGLUT4[2.4]-
CAT
transgene was also assessed in these animals. Fasting was observed to decrease
CAT
activity in white adipose tissue which was super-induced upon refeeding. These alterations in
CAT
expression occurred in parallel to the changes in endogenous mouse
GLUT4
mRNA levels. Although
CAT
expression in skeletal muscle and brown adipose tissue was unaffected, the endogenous mouse
GLUT4
mRNA was also refractory to the effects of fasting/refeeding in these tissues. These data demonstrate that 2.4 kilobases of the 5'-flanking region of the human
GLUT4
gene contain all the necessary sequence elements to confer tissue-specific expression and at least some of the sequence elements controlling the hormonal/metabolic regulation of this gene.
...
PMID:Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. 160 40
Adipose tissue and skeletal and heart muscle, which exhibit insulin-stimulated glucose uptake, express a specific, insulin-responsive glucose transporter. Previously, a cDNA (GT2) encoding this protein was isolated from a mouse 3T3-L1 adipocyte library and was sequenced. Here we report the isolation and characterization of the corresponding mouse gene designated
GLUT4
. The
GLUT4
gene spans 7 kilobases and consists of 11 exons and 10 introns. The start site of transcription was mapped 180 nucleotides upstream of the initial methionine codon. The
GLUT4
promoter contains four potential binding sites for the nuclear transcription factor Sp1 as well as a CCAAT box. DNase I footprinting of the
GLUT4
promoter with nuclear extracts from undifferentiated and differentiated 3T3-L1 cells revealed that a differentiation-specific nuclear factor binds in the region at position -258 relative to the start site of transcription. Purified CCAAT/enhancer binding protein (C/EBP) was found to bind at the same position. Transient cotransfection into 3T3-L1 preadipocytes of a
GLUT4
promoter-
chloramphenicol acetyltransferase
gene construct that contains the C/EBP binding site, together with a C/EBP expression vector, revealed that C/EBP trans-activates the
GLUT4
promoter. We suggest that C/EBP plays an important role in tissue-specific, as well as metabolic, regulation of the insulin-responsive glucose transporter gene.
...
PMID:Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein. 240 78
We previously reported that 2400 base pairs (bp) of 5'-flanking DNA is sufficient for tissue-specific and hormonal/metabolic regulation of the human
GLUT4
gene in transgenic mice (Liu, M.-L., Olson, A. L., Moye-Rowley, W. S., Buse, J. B., Bell, G. I., and Pessin, J. E. (1992) J. Biol. Chem. 267, 11673-11676). To further define the DNA sequences required for
GLUT4
expression, we generated transgenic mice carrying 1975, 1639, 1154, 730, and 412 bp of the
GLUT4
5'-flank (hG4) fused to the
chloramphenicol acetyltransferase
(
CAT
) reporter gene. The 1975-hG4-
CAT
, 1639-hG4-
CAT
, and 1154-hG4-
CAT
constructs were expressed in a tissue-specific manner identical to the endogenous murine
GLUT4
mRNA. Regulation of these reporter gene constructs in insulin-deficient diabetes also paralleled the endogenous gene. In contrast, 730-hG4-
CAT
was expressed at high levels only in skeletal muscle and at low levels in all of the other tissues examined. Additionally, expression of 412-hG4-
CAT
was completely unrestricted. Neither the 730-hG4-
CAT
nor the 412-hG4-
CAT
reporter genes displayed any insulin-dependent regulation. These data demonstrate that a skeletal muscle-specific DNA element is located within 730 bp of the
GLUT4
5'-flanking DNA but that 1154 bp is necessary to direct the full extent of tissue-specific and insulin-dependent regulation of the human
GLUT4
gene in transgenic mice.
...
PMID:Transcriptional regulation of the human GLUT4 gene promoter in diabetic transgenic mice. 755 12
We have previously reported that innervation-dependent basal contractile activity regulates in an inverse manner the expression of GLUT1 and
GLUT4
glucose transporters in skeletal muscle. Based on the facts that muscle innervation decreases and muscle denervation increases cAMP levels, we investigated whether cAMP might mediate the effects of innervation/denervation on glucose transporter expression. Treatment of L6E9 myotubes with 8-bromo-cAMP, forskolin, or monobutyryl-8-bromo-cAMP led to a marked decrease in
GLUT4
protein levels; 8-bromo-cAMP also diminished
GLUT4
messenger RNA (mRNA), suggesting pretranslational repression. In contrast, L6E9 myoblasts and myotubes responded to 8-bromo-cAMP or forskolin by increasing the cell content of GLUT1 protein. Induction of GLUT1 protein was a consequence of the activation of different mechanisms in myoblast and myotube cells; whereas 8-bromo-cAMP treatment caused a substantial increase in GLUT1 mRNA in myoblasts, no change in GLUT1 mRNA was detected in myotubes. The increase in GLUT1 mRNA in L6E9 myoblasts induced by 8-bromo-cAMP was the result of transcriptional activation, as concluded from transfection analysis of 2.1 kilobases of the rat GLUT1 gene promoter fused to the bacterial
chloramphenicol acetyltransferase
gene. Furthermore, the stimulatory effect of 8-bromo-cAMP on the transcriptional activity of the GLUT1 promoter required a 33-bp sequence lying 5' upstream of the transcription start site. In all, cAMP inversely regulates
GLUT4
and GLUT1 glucose transporter expression in muscle cells. Furthermore, our results suggest that down-regulation of
GLUT4
expression and up-regulation of GLUT1 expression in muscle associated with denervation are partly attributable to cAMP.
...
PMID:Cyclic adenosine 3',5'-monophosphate regulates GLUT4 and GLUT1 glucose transporter expression and stimulates transcriptional activity of the GLUT1 promoter in muscle cells. 916 44
We have previously demonstrated that important regulatory elements responsible for regulated expression of the human
GLUT4
promoter are located between -1154 and -412 relative to transcription initiation (Olson, A. L., and Pessin, J. E. (1995) J. Biol. Chem. 270, 23491-23495). Through further analysis of this promoter regulatory region, we have identified a perfectly conserved myocyte enhancer factor 2 (MEF2)-binding domain (-CTAAAAATAG-) that is necessary, but not sufficient, to support tissue-specific expression of a
chloramphenicol acetyltransferase
reporter gene in transgenic mice. Biochemical analysis of this DNA element demonstrated the formation of a specific DNA-protein complex using nuclear extracts isolated from heart, hindquarter skeletal muscle, and adipose tissue but not from liver. DNA binding studies indicated that this element functionally interacted with the MEF2A and/or MEF2C MADS family of DNA binding transcription factors. MEF2 DNA binding activity was substantially reduced in nuclear extracts isolated from both heart and skeletal muscle of diabetic mice, which correlated with decreased transcription rate of the
GLUT4
gene. MEF2 binding activity completely recovered to control levels following insulin treatment. Together these data demonstrated that MEF2 binding activity is necessary for regulation of the
GLUT4
gene promoter in muscle and adipose tissue.
...
PMID:Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. 960 35
Fetal brown adipocytes cultured in a serum-free medium, containing 5 mM glucose, expressed both
GLUT4
and GLUT1 glucose transporters at the mRNA and protein level. Treatment with either insulin or insulin-like growth factor (IGF)-I at physiological concentrations up-regulates the expression of the
GLUT4
gene, producing a time-dependent mRNA accumulation (7-fold increase at 24 h) and a 2.5-fold increase in the amount of protein in the total membrane fraction. However, insulin treatment down-regulates GLUT1 mRNA and protein expression. Moreover, either insulin or IGF-I transactivates a full-promoter
GLUT4
-
chloramphenicol acetyltransferase
gene (CAT) construct transiently transfected to the cells, without affecting GLUT1-CAT activity. In consequence, insulin treatment for 24 h increased by 3-fold the basal glucose uptake. Inhibition of phosphoinositide (PI) 3-kinase activity with chemical agents such as wortmannin or LY294002 partially blocked insulin-induced
GLUT4
mRNA accumulation, insulin-induced
GLUT4
protein content,
GLUT4
-CAT transactivation and glucose uptake. Furthermore, co-transfection of brown adipocytes with a dominant-negative form of PI 3-kinase precluded the transactivation of the
GLUT4
promoter by insulin. However, inhibition of p70S6 kinase (p70(s6k)) with rapamycin or of mitogen-activated protein kinase (MAPK) with PD098059 does not preclude insulin effects on
GLUT4
gene expression or glucose uptake. Our results show for the first time a positive effect of insulin on
GLUT4
gene expression in fetal brown adipocytes, suggesting the existence of insulin response element(s) in its promoter. Moreover, PI 3-kinase, but not p70(s6k) or MAPK, is an essential requirement for insulin regulation of
GLUT4
gene expression.
...
PMID:Insulin and insulin-like growth factor I up-regulate GLUT4 gene expression in fetal brown adipocytes, in a phosphoinositide 3-kinase-dependent manner. 989 82
Treatment of foetal brown adipocytes in primary culture with either dexamethasone or insulin, at physiological concentrations, for 24 h up-regulates the expression of the
GLUT4
gene, producing a synergistic effect on mRNA accumulation (20-fold increase), in the amount of protein in the total membrane fraction (8-fold increase) and in the transactivation of a full-promoter
GLUT4
-
chloramphenicol acetyltransferase
gene ( CAT ) construct (7-fold increase). However, GLUT1 expression remains essentially unmodified regardless of the presence of the hormones. As a consequence, exposure of brown adipocytes to dexamethasone and insulin results in a dramatic increase of glucose uptake (12-fold). Dexamethasone induces the expression of CCAAT/enhancer-binding protein (C/EBP) alpha, insulin promotes myocyte enhancer factor-2 DNA-binding activity and both combined produces a significant increase in C/EBPalpha DNA-binding activity. Moreover, co-transfection with a wild-type C/EBPalpha construct transactivates a full-promoter
GLUT4
- CAT fusion gene, whereas a dominant-negative C/EBPalpha expression vector impairs the hormonal effects. Our results show that the synergism between insulin and glucocorticoids on glucose uptake is a consequence of the activation of the
GLUT4
promoter by the transcription factor C/EBPalpha.
...
PMID:Insulin and dexamethasone induce GLUT4 gene expression in foetal brown adipocytes: synergistic effect through CCAAT/enhancer-binding protein alpha. 1264 95
Tumour necrosis factor (TNF)-alpha impaired insulin induction on
GLUT4
mRNA in foetal brown adipocytes, as demonstrated by quantitative RT-PCR and Northern blot. We have explored the hypothesis that some effects of TNF-alpha could be mediated by the generation of ceramide, since TNF-alpha treatment induced the production of ceramide in these primary cells. A short-chain ceramide analogue, C2-ceramide, precluded insulin-induced
GLUT4
mRNA accumulation and
GLUT4
-
chloramphenicol acetyltransferase
(
CAT
) full promoter activation. Moreover, inhibition of the ceramide biosynthesis with fumonisin B, which inhibits ceramide synthase, completely restored insulin-induced
GLUT4
mRNA and protein accumulation as well as
GLUT4
-
CAT
transactivation in the presence of TNF-alpha. In consequence, TNF-alpha-induced insulin resistance on glucose uptake was completely alleviated. In addition, TNF-alpha down-regulated insulin-induced CCAAT/enhancer binding protein (C/EBP)-alpha gene expression and DNA binding activity, but fumonisin B precludes these effects. Furthermore, co-transfection with a wild-type C/EBP-alpha construct transactivates
GLUT4
-
CAT
construct. Our results indicate that de novo ceramide produced by TNF-alpha-induced insulin resistance on
GLUT4
gene expression in brown adipocytes by interfering C/EBP-alpha expression, a transcription factor essential for the expression of
GLUT4
.
...
PMID:Ceramide mediates TNF-alpha-induced insulin resistance on GLUT4 gene expression in brown adipocytes. 1675 99